Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 18;14:1516. doi: 10.1038/s41467-023-36979-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A Expression (median fluorescence intensity of at least three biological replicates for each cell line divided by fluorescence minus one control, MFI/FMO) of MHC-II on PD1 PROGs (n = 22), 72 h after treatment with BSA control or IFNγ (1000 U/ml). SCC16-0016 and PD1 PROGs with low MHC-II expression are highlighted in orange. B Representative histograms showing melanoma MHC-II expression in tumor dissociates of B2M-mutant SCC13-0156 and SMU-092 (unshaded red histograms) compared to autologous TILs (blue). MHC-II expression on B2M-wild-type SCC15-0111 and WMD-084 shown for comparison (shaded red histograms). C Accumulation of CIITA protein in 5 PD1 PROGs, 24 h after treatment with BSA control (−) or IFNγ (1000 U/ml). Experiment repeated independently at least three times. D Scatterplot showing correlation of CIITA transcript expression pre and post IFNγ treatment in 22 PD1 PROG cell lines. PD1 PROGs with low CIITA expression (n = 5) are highlighted in orange. Correlation calculated using two-sided Spearman’s rank correlation coefficient, exact p-values shown. E Scatterplot showing correlation of MHC-II expression (MFI/FMO, MFI post IFNγ treatment) with expression of CIITA transcript (post IFNγ treatment) in PD1 PROGs (n = 22). PD1 PROGs with low MHC-II expression are highlighted in orange. Correlation calculated using two-sided Spearman’s rank correlation coefficient, exact p-values shown. F Accumulation of CIITA protein in the SCC11-0270 and SMU17-0263 PD1 PROGs, 72 h after treatment with BSA control, panobinostat (HDACi, 25 nM) in the presence or absence of IFNγ (1000 U/ml). Experiment repeated independently at least three times. G Representative histograms showing melanoma MHC-II expression in MHC-II^low SCC17-0263 and SCC11-0270 PD1 PROGs treated with 1000 U/ml IFNγ (shaded red histograms) or IFNγ with panobinostat (HDACi; shaded blue histograms). H Bar graphs show relative MHC-I and MHC-II expression (IFNγ/control-treated) in SCC17-0263 and SCC11-0270 PD1 PROGs treated with 1000 U/ml IFNγ or IFNγ with panobinostat (HDACi). Individual values and mean ± sd of three biological replicates are shown and paired, two-tailed t-test was used to compare the data, exact p-values shown. Source data are provided as a Source Data file.